Mike Dombeck is currently Manager, Portfolio and Business Analysis, for GlaxoSmithKline, where he has responsibility for evaluating investment tradeoffs among GSK’s biopharmaceuticals, neurosciences, infectious disease, and rare disease portfolios. Immediately prior to joining GSK, he worked as Deputy Director of Market Research and Competitive Intelligence for Talecris Biotherapeutics, supporting business development and portfolio management.  Mike also brings experience from his work as a project manager for Campbell Alliance, advising North American and European biotech and pharmaceutical companies on licensing, acquisitions, and business development processes, and as Director of Business Development for DarPharma, a schizophrenia and Parkinson’s disease spinout from the University of North Carolina at Chapel Hill.  He began his career working in Health Outcomes and Pharmacoeconomics with Research Triangle Institute’s Health Solutions division.

In addition, Mike is a co-founder of Cempra Pharmaceuticals, a local start-up developing a new class of fluoroketolide antibiotics, and an advisor to Precision Biosciences, a Duke University spinout developing Directed Nuclear Editing (DNE) technology. Mike completed both his undergraduate and graduate studies at Duke, with an MBA and Master of Public Policy, in addition to a BS in biology and health policy.